Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Glaukos Corporation (GKOS) Guidance & Earnings Results

On 2026-07-29 Glaukos Corporation raised guidance: "FY2026 global consolidated revenues of $680 - $700 million…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

GKOSGlaukos CorporationFollow GKOS — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
10.6B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
28 Oct, in 4 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
29 Jul 26RaisedFY2026 global consolidated revenues of $680 - $700 million expected · full year
29 Apr 26RaisedFY2026 guidance $620-635M · full year
17 Feb 26RaisedFY2026 revenue guidance of $600-620M, implying ~19% growth at midpoint · full year
29 Oct 25RaisedFY2025 guidance raised to $490-495M from $480-486M; FY2026 preliminary $600-620M · full year
30 Jul 25RaisedFY2025 global consolidated revenues raised to $480-486M from $475-485M · full year

Glaukos Corporation — questions

What guidance did Glaukos Corporation give?
On 2026-07-29: "FY2026 global consolidated revenues of $680 - $700 million expected"
When does Glaukos Corporation report earnings?
Glaukos Corporation's next earnings report is expected on 2026-10-28.

Every figure on this page comes from Glaukos Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.